InsidersTradesSigma
Follow the Vitae Pharmaceuticals, Inc stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 25 January 2016 (Levée d'options). Among the most active insiders: Gregg Richard. All data is accessible without an account.
Analysts rate Vitae Pharmaceuticals, Inc Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Vitae Pharmaceuticals, Inc 是一家生物制药公司，专注于开发遗传疾病和代谢紊乱的治疗方法。该公司在纳斯达克上市，股票代码为VTAE。